VIDEO: Access to biosimilars, on-label bevacizumab important for retinal disease treatment
Click Here to Manage Email Alerts
NEW YORK — In this Healio Video Perspective from OSN New York Retina, Rishi P. Singh, MD, FASRS, of Cleveland Clinic Florida discusses the need for anti-VEGF biosimilars and the possibility of on-label bevacizumab.
According to Singh, increased availability of anti-VEGF biosimilars will improve patient access and decrease cost of care. He also discussed the impact of the recent shortage of compounded Avastin (bevacizumab, Genentech) on patient treatment.
“We rely on this drug heavily for our patients as they enter into our treatment armamentarium for diabetic macular edema, retinal vein occlusion and exudative [age-related macular degeneration],” he said.
Collapse
Singh RP. Biosimilar and on label bevacizumab update. Presented at: OSN New York and OSN New York Retina; Nov. 8-10, 2024; New York.
Read more about
Click Here to Manage Email Alerts